...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Technology in cancer research & treatment. >Sequential treatment of superior vena cava syndrome caused by of non-small cell carcinoma lung cancer (NSCLC) with vascular stenting and iodine-125 implantation.
【24h】

Sequential treatment of superior vena cava syndrome caused by of non-small cell carcinoma lung cancer (NSCLC) with vascular stenting and iodine-125 implantation.

机译：非小细胞肺癌（NSCLC）血管支架置入和碘125植入治疗序贯上腔静脉综合征。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Feasibility and efficacy of sequentially performed endovascular stenting and Iodine-125 brachytherapy for malignant superior vena cava syndrome (SVCS) were evaluated. Thirty-four patients with malignant SVCS caused by NSCLC underwent sequential treatment of endovascular stenting and Iodine-125 brachytherapy. SVCS was diagnosed in all patients by CT images or vena-cavography. Pathology diagnosis was acquired by image guided biopsy. Endovascular stent placement was performed as first-line treatment for symptom relief. CT-guided Iodine-125 seed implantation performed 24hr after stenting. Clinical end points were resolution of symptoms and local efficacy of primary malignancy regression. Symptom relief rate was >90% after 24hr and 97% after 3 months. No migration of seeds or restenosis occurred in any patient. The local efficacy (defined as either partial or complete response) was 53%, 79%, 88% and 74% after 1, 3, 6 and 12 months, respectively. Mean SVCS-free survival time was 305 days (range 120-960 days). Two patients were still alive at the time of this writing, Thirty-one died from progression and one died from acute heart disease. Sequentially performed endovascular stenting and Iodine-125 brachytherapy provides a safe and effective alternative for malignant SVCS caused by NSCLC.
机译：评估了序贯进行血管内支架置入和Iodine-125近距离放射治疗恶性上腔静脉综合征（SVCS）的可行性和有效性。由NSCLC引起的34例恶性SVCS患者接受了血管内支架置入和Iodine-125近距离放射治疗的序贯治疗。所有患者均通过CT图像或腔静脉造影诊断为SVCS。通过图像引导活检获得病理诊断。血管内支架置入术是缓解症状的一线治疗。支架置入后24小时进行CT引导的碘125种子植入。临床终点是症状的缓解和原发性恶性肿瘤消退的局部疗效。 24小时后症状缓解率> 90％，3个月后症状缓解率> 97％。任何患者均未发生种子迁移或再狭窄。在1、3、6和12个月后，局部疗效（定义为部分或完全缓解）分别为53％，79％，88％和74％。无SVCS的平均生存时间为305天（范围为120-960天）。在撰写本文时，有2名患者还活着，其中31名死于进展，1名死于急性心脏病。顺序进行血管内支架置入和Iodine-125近距离放射治疗为NSCLC引起的恶性SVCS提供了安全有效的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号